Eli Lilly and Company $LLY Shares Sold by GTS Securities LLC

Key Points

• GTS Securities cut its Eli Lilly stake by 52.6% in the second quarter, selling 1,955 shares and retaining 1,764 shares valued at approximately $2.1 million. Institutional investors and hedge funds collectively own 82.53% of the stock.
• Eli Lilly reported strong quarterly results: earnings of $8.38 per share exceeded estimates by $1.98, while revenue rose 47.7% year over year to $22.97 billion. The company also maintained fiscal 2026 guidance of $35.50–$36.50 in EPS.
• Shares opened at $1,160.98, with a market capitalization of about $1.09 trillion, while analysts maintain a “Moderate Buy” consensus and an average price target of $1,292.18. The company declared a quarterly dividend of $1.73 per share, yielding 0.6%.

GTS Securities LLC lowered its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 52.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,764 shares of the company's stock after selling 1,955 shares during the quarter. GTS Securities LLC's holdings in Eli Lilly and Company were worth $2,116,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. Alyeska Investment Group L.P. purchased a new position in Eli Lilly and Company in the second quarter valued at $688,000. Flputnam Investment Management Co. raised its holdings in Eli Lilly and Company by 20.1% in the second quarter. Flputnam Investment Management Co. now owns 88,942 shares of the company's stock valued at $106,680,000 after acquiring an additional 14,860 shares in the last quarter. Wedbush Securities Inc. raised its holdings in Eli Lilly and Company by 1.1% in the second quarter. Wedbush Securities Inc. now owns 18,603 shares of the company's stock valued at $22,313,000 after acquiring an additional 198 shares in the last quarter. Rational Advisors Inc. lifted its stake in Eli Lilly and Company by 106.5% in the second quarter. Rational Advisors Inc. now owns 3,236 shares of the company's stock worth $3,881,000 after acquiring an additional 1,669 shares during the last quarter. Finally, Bluefin Capital Management LLC purchased a new position in Eli Lilly and Company in the second quarter worth approximately $463,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $1,160.98 on Friday. The firm has a market capitalization of $1.09 trillion, a P/E ratio of 38.96, a P/E/G ratio of 1.44 and a beta of 0.50. Eli Lilly and Company has a 52 week low of $712.05 and a 52 week high of $1,292.65. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The firm's 50 day moving average is $1,192.90 and its two-hundred day moving average is $1,069.12.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, topping the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The business had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. During the same quarter in the previous year, the firm earned $6.31 EPS. The company's revenue was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Research analysts forecast that Eli Lilly and Company will post 36.35 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company's dividend payout ratio is currently 23.22%.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the firm's stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the transaction, the executive vice president owned 11,875 shares of the company's stock, valued at approximately $14,131,250. This trade represents a 29.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of Eli Lilly and Company stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the sale, the executive vice president owned 54,147 shares in the company, valued at $63,628,139.70. This trade represents a 10.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 13,500 shares of company stock worth $15,958,170 over the last 90 days. Corporate insiders own 0.14% of the company's stock.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Merida acquisition broadens Lilly beyond GLP-1 drugs. Lilly agreed to acquire Merida Biosciences for up to $2.875 billion, adding a platform designed to selectively degrade disease-causing autoantibodies while preserving normal immune function. The deal provides an early-stage pipeline in autoimmune and allergy diseases and represents Lilly’s 10th transaction of 2026, reinforcing management’s effort to diversify its growth drivers. What Does Eli Lilly Gain From Its $2.88 Billion Immunology Deal?
• Positive Sentiment: Clinical and business-development momentum remains favorable. Lilly highlighted its Phase 1 inflammation candidate LY5625575, while its Centessa subsidiary reached a late-stage development milestone for an orexin receptor 2 agonist program. The milestone triggers an $8.6 million payment to partner Nxera Pharma and signals continued progress in Lilly’s broader pipeline. Eli Lilly’s New Phase 1 Inflammation Drug LY5625575 Enters the Spotlight
• Positive Sentiment: Mounjaro expansion into Africa creates a long-term opportunity. Lilly’s partnership with Aspen Pharmacare is initially expected to represent only about 1.25% of quarterly sales, but the launch could establish distribution and market access for Mounjaro across additional African markets. The near-term revenue contribution is small, while the strategic expansion potential is larger. Lilly’s African Mounjaro Push Starts at 1.25% of Quarterly Sales
• Neutral Sentiment: Valuation and execution remain key considerations. Recent coverage points to sustained GLP-1 momentum and Lilly’s strong latest quarter, but the stock trades at a premium valuation. The Merida deal and several early-stage programs could create future growth, although they will require successful clinical development and commercialization.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on LLY shares. Bank of America increased their price objective on shares of Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the company a "buy" rating in a research report on Friday, July 10th. Berenberg Bank lifted their price objective on shares of Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the stock a "hold" rating in a research report on Monday, June 22nd. Jefferies Financial Group boosted their target price on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the stock a "buy" rating in a research note on Tuesday, June 9th. Wolfe Research reissued an "outperform" rating and issued a $1,350.00 target price on shares of Eli Lilly and Company in a report on Thursday, May 21st. Finally, BMO Capital Markets upgraded Eli Lilly and Company from an "outperform" rating to a "buy" rating in a research note on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $1,292.18.

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source